Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 13 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The foreign exchange assumptions were changed from ¥165 per euro to ¥182 and from ¥145 per US dollar to ¥159, incorporating strong first-half performance in the diabetes management and life sciences businesses, the effects of cost reductions, US tariff refunds and foreign exchange gains. The revision also reflects lower electronic medical record revenue due to server supply shortages affecting healthcare IT solutions, as well as stagnant demand for equipment in the pathology business.
| Item | Details |
|---|---|
| Net Sales | ¥359,700 million → ¥366,000 million（+1.8%） |
| Operating profit | ¥27,000 million → ¥33,000 million（+22.2%） |
| Profit attributable to owners of the parent | ¥15,400 million → ¥18,000 million（+16.9%） |
| Net income per share | ¥121.73 → ¥141.74（+16.4%） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 May 2026 |
| Previous-period results | Fiscal year ended March 2026: revenue ¥364,403 million, operating profit ¥22,688 million, profit before tax ¥6,390 million, profit for the year ¥219 million, profit for the year attributable to owners of the parent ¥492 million, basic earnings per share ¥3.90, adjusted EBITDA ¥51,959 million |
| Reason for the revision | The foreign exchange assumptions were changed from ¥165 per euro to ¥182 and from ¥145 per US dollar to ¥159, incorporating strong first-half performance in the diabetes management and life sciences businesses, the effects of cost reductions, US tariff refunds and foreign exchange gains. The revision also reflects lower electronic medical record revenue due to server supply shortages affecting healthcare IT solutions, as well as stagnant demand for equipment in the pathology business. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main reasons were that the foreign exchange assumptions for the full-year earnings forecast were changed from ¥165 per euro to ¥182 and from ¥145 per US dollar to ¥159, first-half performance in the diabetes management and life sciences businesses was strong, and the effects of cost reductions, US tariff refunds and foreign exchange gains were incorporated. The revision also reflects lower electronic medical record revenue due to server supply shortages affecting healthcare IT solutions, as well as stagnant demand for equipment in the pathology business.